<?xml version="1.0" encoding="UTF-8"?>
<p>No approved drug regimen has been introduced to treat infected cases so far, antiviral treatments are used to alleviate the disease symptoms. Studies on Remedesevir, as an antiviral agent, revealed its in vitro activity against the COVID-19 virus and its safety was proven in Ebola trials. Another proposed treatment is Chloroquine, an old drug for treatment of malaria, with apparent effectiveness and acceptable safety against COVID-19 associated pneumonia (
 <xref rid="B48" ref-type="bibr">48</xref>,
 <xref rid="B49" ref-type="bibr">49</xref>). Evaluating the efficacy of anti-influenza drugs such as Umifenovir and Oseltamivir against COVID-19 virus is interesting but lacks any biological plausibility. Using monoclonal antibodies has been suggested as an attractive choice among inactive prophylactic methods; however, its effectiveness has not been proven in other viral respiratory diseases and influenza, yet (
 <xref rid="B50" ref-type="bibr">50</xref>,
 <xref rid="B51" ref-type="bibr">51</xref>).
</p>
